(Q34841680)

4 August 2017

1 reference

title

Anti-obesity drug development (English)

1 reference

4 August 2017

0 references

Harold Bays

1

1 reference

4 August 2017

Carlos Dujovne

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

11

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

1189-1204

1 reference

Morbidity of severe obesity

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The treatment of obesity in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Thermogenic effects of sibutramine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Behavioral treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

21 January 2018

Novel anti-obesity drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The role of NPY in metabolic homeostasis: implications for obesity therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Nonhypoglycemic drug reactions of agents used to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Reversing adipocyte differentiation: implications for treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

A transgenic model of visceral obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The effects of obesity, smoking, and drinking on medical problems and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Does obesity contribute as much to morbidity as poverty or smoking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Bias, Discrimination, and Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

The endocrinology of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1189

10.1517/13543784.11.9.1189

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference